PMC:7195088 / 33788-34332
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T49 | 70-78 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
| T50 | 279-283 | Body_part | denotes | IL-1 | http://purl.org/sig/ont/fma/fma86583 |
| T51 | 279-281 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T174 | 118-126 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T175 | 417-425 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T189 | 133-138 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
| T190 | 432-437 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T460 | 46-56 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
| T461 | 133-138 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T462 | 241-252 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
| T463 | 279-281 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T465 | 293-303 | Chemical | denotes | antagonist | http://purl.obolibrary.org/obo/CHEBI_48706 |
| T466 | 367-378 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
| T467 | 432-437 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T272 | 128-177 | Sentence | denotes | Open-label RCT (NCT04324021, not yet recruiting). |
| T273 | 178-224 | Sentence | denotes | Primary endpoint: treatment success at day 15. |
| T274 | 225-426 | Sentence | denotes | • Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. |
| T275 | 427-476 | Sentence | denotes | Open-label RCT (NCT04330638, not yet recruiting). |
| T276 | 477-544 | Sentence | denotes | Primary endpoint: time to clinical improvement (follow-up 15 days). |